Wire · opportunities
AbbVie's Cerevel buyout delivers as FDA gives go-ahead to 1st-in-class Juvmo in ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 28 September 2026 · Fusion42 review
AbbVie received FDA approval for Juvmo (tavapadon), a first-in-class selective D1/D5 receptor drug for Parkinson’s disease, marking a significant dopaminergic breakthrough after acquiring Cerevel Therapeutics. Juvmo offers a novel treatment option with fewer side effects compared to existing therapies, addressing motor fluctuations without the burdens of earlier dopamine receptor drugs.
This Wire brief sits within Fusion42's coverage of Biotech, and 5 sources have reported it.
◆ ◆ The Wire takeaway
AbbVie’s Parkinson’s drug approval opens the gate for new treatment standards that sidestep traditional side effects. You can capitalise on this if you build therapies or support tools for Parkinson’s that pivot away from legacy dopamine agonists.
◆ Coverage
5 sources · 28 Sep 2026
◆ Related on Wire
◆ Topics